Morning Briefing
Summaries of health policy coverage from major news organizations
Bill Gates To Build Factories For 7 Leading Vaccines To Help Accelerate Long Journey From Development To Public Use
Microsoft Corp. co-founder Bill Gates said his foundation will spend billions of dollars to fund the construction of factories for the most promising efforts to develop a vaccine to combat the novel coronavirus. Mr. Gates, a billionaire philanthropist who is one the richest people in the world, said the Bill and Melinda Gates Foundation will work with seven makers of a possible vaccine to build these factories. Mr. Gates, who announced the efforts in an appearance on 鈥淭he Daily Show With Trevor Noah鈥 Thursday, acknowledged that billions of dollars would be wasted on vaccines that won鈥檛 pan out. (Calfas, 4/5)
Meanwhile 鈥
A vaccine that was developed a hundred years ago to fight the tuberculosis scourge in Europe is now being tested against the coronavirus by scientists eager to find a quick way to protect health care workers, among others. The Bacillus Calmette-Guerin vaccine is still widely used in the developing world, where scientists have found that it does more than prevent TB. The vaccine prevents infant deaths from a variety of causes, and sharply reduces the incidence of respiratory infections. The vaccine seems to 鈥渢rain鈥 the immune system to recognize and respond to a variety of infections, including viruses, bacteria and parasites, experts say. (Rabin, 4/3)
It seems like an agency tailor-made for a crisis like the coronavirus pandemic. The Biomedical Advanced Research and Development Authority, or BARDA, was created to invest in drug development projects that private industry wouldn鈥檛 touch, such as anthrax vaccines and therapies for Ebola, Zika, or swine flu. Lawmakers were so confident that BARDA could help scientists develop a coronavirus vaccine, therapy, or even a diagnostic test that Congress has showered the agency with a $3.5 billion boost in funding, more than tripling its total budget. But consultants and experts in biotech and in academia told STAT they had serious concerns about BARDA鈥檚 preparedness to absorb the massive new workload it will take to identify targets for a coronavirus vaccine or therapy. (Florko, 4/6)